ArticleESMO gastrointestinal oncology2026

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies.

Kenichi YoshimuraPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.